E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment for Schizophrenia in Adolescents |
|
E.1.1.1 | Medical condition in easily understood language |
Treatment for Schizophrenia in Adolescents |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10039626 |
E.1.2 | Term | Schizophrenia |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This study has two portions: Phase IIb and Phase III: The primary objective of the Phase IIb portion of this study is to evaluate NaBen® (sodium benzoate) (1000 mg/day) safety and effectiveness and to determine the final sample size needed in order to proceed with the Phase III part of this trial. The primary objective of the Phase III portion of this study is to evaluate the effectiveness of NaBen® (sodium benzoate) (1000 mg/day), as compared to Placebo (0 mg/day), in improving the negative and positive symptoms associated with schizophrenia in adolescents. |
|
E.2.2 | Secondary objectives of the trial |
This study has two portions: Phase IIb and Phase III: Phase IIb – The secondary objective of this portion of the study is to evaluate the safety and tolerability of NaBen® (sodium benzoate) (1000 mg/day) as compared to Placebo (0 mg/day). Phase III – The secondary objective of this portion of the study is to evaluate the safety and tolerability of NaBen® (sodium benzoate) (1000 mg/day), as compared to Placebo (0 mg/day). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects are required to meet all of the following criteria for randomization into the study. 1. Male or female subjects who are between 12 and 17 years of age inclusive 2. Physician confirmed DSM-IV or -V diagnosis of schizophrenia based on the MINI International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders Studies for Children and Adolescents, version 6.0 (MINI-KID, Version 6.0) (Sheehan, 2010) (refer to Appendix 19.1) 3. Are clinically stable with residual symptoms. Residual symptoms will be defined as a total score of ≥ 60 of PANSS and a score of ≥ 40 for SANS 4. An unchanged antipsychotic medication regimen for at least eight (8) weeks prior to randomization into the study and expected to remain unchanged during the study (longer for depot or long-acting antipsychotics: ten (10) months for Aripiprazole (Maintena®) and Paliperidone (Xeplion®); six (6) months for Olanzapine pamoate monohydrate (Zypadhera®); and at least 6 times duration of the reported half life or minimum four (4) months for other depot or long-acting antipsychotics) 5. In good general physical health and all physical exam, neurological exam and laboratory assessments (urine/blood routine, biochemical tests and electrocardiogram [ECG]) are clinically unremarkable per the Investigator 6. Subject has a negative urine illicit drug screening test 7. Subject understands and is willing to sign the IAF prior to study entry and agrees to be available for all the study visits 8. The subject’s guardian understands and is willing to sign the ICF prior to study entry and agrees to be available for all the study visits 9. Must not be a danger to self or others and must have family support available to be maintained as outpatients |
|
E.4 | Principal exclusion criteria |
Subjects meeting any of the following criteria will be excluded from randomization into the study: 1. Meets the DSM-IV or -V criteria at screening for mental retardation, dissociative disorder, bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder, autistic disorder, or primary substance-induced psychotic disorder. Other comorbid disorders; e.g., attention-deficit hyperactivity disorder (ADHD), are allowed as long as schizophrenia is the primary diagnosis and the comorbid disorder(s) do not require medication. 2. Subjects whose illness was resistant to antipsychotics according to prior trials of two different antipsychotics of adequate dose 3. History of epilepsy, head trauma, or neurological illness other than Tourette’s syndrome 4. History of allergic reaction to sodium benzoate 5. Serious medical illnesses such as acute or chronic renal disease, liver failure or heart disease that, in the opinion of the Investigator, may interfere with the conduct of the study. 6. Current substance abuse or positive urine illicit drug screening or history of substance dependence (including alcohol, but excluding nicotine and caffeine) in the past three (3) months. 7. Inability to follow protocol 8. Body Mass Index (BMI) > 35 9. Female subjects who are pregnant (as confirmed by urine pregnancy test performed at screening Visit) or are nursing, or who do not agree to abstinence or birth control during the study 10. Cancer within the last three (3) years except for basal cell carcinoma and squamous cell carcinoma 11. Previous participation in an intervention trial within 30 days of randomization 12. Decrease in the PANSS total score by more than 10 percent using PANSS evaluations performed at Screening Visit 1 and Screening Visit 3
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint for the study is: Mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score after six (6) weeks of treatment |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 6 weeks of treatment |
|
E.5.2 | Secondary end point(s) |
SECONDARY EFFICACY ENDPOINTS • Percent change from baseline in Positive and Negative Syndrome Scale (PANSS) total score from baseline after 6 weeks of treatment • Percentage of subjects with 20% or more reduction in Positive and Negative Syndrome Scale (PANSS) total score from baseline after six (6) weeks of treatment • Percent change in Positive and Negative Syndrome Scale (PANSS) subscales • Percent change in Scale for Assessment of Negative Symptoms (SANS) total scores • Percent change in Scale for Assessment of Negative Symptoms (SANS) subscale scores
ADDITIONAL EFFICACY ENDPOINTS • Percent change in Children's Global Assessment Scale (CGAS) • Percent change in Clinical Global Impression-Severity (CGI-S) • Percent change in Children's Depression Rating Scale-Revised (CDRSR)
SAFETY ASSESSMENTS • Incidence of Treatment-Emergent Adverse Events (TEAE) • Incidence of withdrawals from the study due to TEAEs • Percent change in Simpson-Angus extrapyramidal side effects (SAS) scale • Percent change in Abnormal Involuntary Movement Scale (AIMS) • Percent change in Barnes Akathisia Rating Scale (BARS) • Assessment of suicidality per the Columbia-Suicide Severity Rating Scale (C-SSRS) • Changes and shifts in laboratory measurements over time • Changes in vital signs and weight over time • Changes in ECG parameters over time |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After 6 weeks of randomized treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Poland |
Taiwan |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |